Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Telehealth study of patient portal e-visits by Medicare participants shows few had an interaction for which their provider billed them.

At-home test can detect tumor DNA fragments in urine samples, providing a non-invasive alternative to traditional blood-based biomarker tests

New website to help adolescents with disabilities learn about reproductive health.

Using a chip to process blood samples, doctors can monitor the amount of cancer cells in a patient’s blood to determine how well a treatment is working by the fourth week, according to a new study.

Cases of kidney stones in children are increasing, but parents can minimize the chances their kids develop them.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

A Michigan Medicine urogynecologist discusses what urinary tract infections are, how they are treated and what new research is on the horizon.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

For people with expensive prescription drugs, switching plans could save them thousands of dollars in copays. And a simple tool can help people easily compare out-of-pockets expenses for anyone with a Medicare Part D prescription plan.

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a Michigan Medicine study finds.

There are 13 U-M graduate medical education programs ranked in the top 10 by Doximity.

An analysis finds that up to millions of dollars could be saved annually on cancer immunotherapy treatments across the Veterans Health Administration by reconsidering how those drugs are delivered.